Skip to search formSkip to main contentSkip to account menu

GSK1278863

National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

BarbituratesGlycine
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Hypoxia-inducible factor for the treatment of anemia in chronic kidney disease
Studies in the field of oxygen-dependent regulation of erythropoiesis provided new data on the pathogenesis of anemia associated… 
2017
2017
A Randomized, Placebo‐ and Positive‐Controlled, Single‐Dose, Crossover Thorough QT/QTc Study Assessing the Effect of Daprodustat on Cardiac Repolarization in Healthy Subjects
Daprodustat (GSK1278863) is a prolyl hydroxylase inhibitor in phase 3 clinical studies for the treatment of anemia associated… 
2016
2016
Overcoming bioanalytical challenges associated with the separation and quantitation of GSK1278863, a HIF-prolyl hydroxylase inhibitor, and its 14 stereoisomeric metabolites.
2016
2016
Therapy: PHD inhibitors correct anaemia in CKD
suggest that oral hypoxia-inducible factor prolyl hydroxylase (PHD) inhibitors might be effective therapies for anaemia in… 
2016
2016
Exposure-response Analysis To Assess The Effect Of Gsk1278863 On Cardiac Repolarization.: Pi-049
2014
2014
Short-term treatment with a novel HIF-prolyl hydroxylase inhibitor (GSK1278863) failed to improve measures of performance in subjects with claudication-limited peripheral artery disease
Hypoxia inducible factor (HIF) stabilization by HIF-prolyl hydroxylase (PHD) inhibitors may improve ischemic conditions such as… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)